The ROE as of September 2024 (TTM) for FibroGen, Inc. (FGEN) is 81.93%

According to FibroGen, Inc.’s latest financial reports and current stock price. The company's current ROE is 81.93%. This represents a change of 267.63% compared to the average of 22.29% of the last 4 quarters.

FibroGen, Inc. (FGEN) Historical ROE (quarterly & annually)

How has FGEN ROE performed in the past?

The mean historical ROE of FibroGen, Inc. over the last ten years is 116.27%. The current 81.93% ROE has changed -29.54% with respect to the historical average. Over the past ten years (40 quarters), FGEN's ROE was at its highest in in the December 2022 quarter at 309.86%. The ROE was at its lowest in in the September 2022 quarter at -349.95%.

FibroGen, Inc. (FGEN) ROE by Quarter and Year

Discovering the peaks and valleys of FibroGen, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

FibroGen, Inc. (FGEN) Average ROE

How has FGEN ROE performed in the past?

The current ROE of FibroGen, Inc. (FGEN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

FibroGen, Inc. (FGEN) ROE vs. Peers

How is FGEN’s ROE compared to its peers?

FibroGen, Inc.’s ROE is greater than Ardelyx, Inc. (-39.73%), greater than Zura Bio Limited (-35.45%), greater than Hepion Pharmaceuticals, Inc. (-328.66%), less than AVROBIO, Inc. (29.68%), greater than Verastem, Inc. (-133.02%), greater than Mereo BioPharma Group plc (-63.39%), greater than Blueprint Medicines Corporation (-85.25%), greater than Agios Pharmaceuticals, Inc. (-47.05%), greater than Day One Biopharmaceuticals, Inc. (-122.70%), less than BioMarin Pharmaceutical Inc. (5.08%), greater than Lyell Immunopharma, Inc. (-33.35%), greater than Cullinan Oncology, Inc. (-28.37%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than Theseus Pharmaceuticals, Inc. (-24.51%), greater than Revolution Medicines, Inc. (-34.57%), greater than Biomea Fusion, Inc. (-91.86%), greater than Stoke Therapeutics, Inc. (-57.89%), greater than Akero Therapeutics, Inc. (-29.56%), greater than Homology Medicines, Inc. (-100.91%), greater than Gossamer Bio, Inc. (-117.33%), greater than Vaxcyte, Inc. (-30.07%), greater than Larimar Therapeutics, Inc. (-37.84%), greater than Syndax Pharmaceuticals, Inc. (-57.42%), greater than Merus N.V. (-36.33%), greater than Sutro Biopharma, Inc. (-97.19%),

Build a custom stock screener for FibroGen, Inc. (FGEN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like FibroGen, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

FibroGen, Inc. (FGEN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like FibroGen, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.